1. Home
  2. NP vs ADPT Comparison

NP vs ADPT Comparison

Compare NP & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NP

Neptune Insurance Holdings Inc.

N/A

Current Price

$19.45

Market Cap

2.9B

Sector

Finance

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$14.01

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NP
ADPT
Founded
2017
2009
Country
United States
United States
Employees
58
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.5B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NP
ADPT
Price
$19.45
$14.01
Analyst Decision
Buy
Strong Buy
Analyst Count
12
9
Target Price
$27.04
$17.78
AVG Volume (30 Days)
470.3K
1.5M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$26.12
$3.98
Revenue Next Year
$15.75
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$14.78
$6.68
52 Week High
$31.75
$20.76

Technical Indicators

Market Signals
Indicator
NP
ADPT
Relative Strength Index (RSI) 36.22 30.91
Support Level $14.78 $12.32
Resistance Level $26.85 $17.52
Average True Range (ATR) 0.98 0.74
MACD 0.06 -0.16
Stochastic Oscillator 2.67 0.66

Price Performance

Historical Comparison
NP
ADPT

About NP Neptune Insurance Holdings Inc.

Neptune Insurance Holdings Inc is a high-growth, data-driven MGA that is revolutionizing the way homeowners and businesses protect against the growing risks of flooding. It offers a range of easy-to-purchase residential and commercial insurance products - including primary flood insurance, excess flood insurance, and parametric earthquake insurance - distributed through a nationwide network of agencies. It underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies, whom the company refer to as capacity providers, that manage both this risk and the associated claims handling.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: